| Bioactivity | Pirozadil is a hypolipidemic agent. | ||||||||||||
| In Vivo | Pirozadil is a hypolipidemic agent. Pirozadil's effect on increasing cerebral blood flow is almost equal to that of papaverine, less than that of nicardipine and much greater than that of the other hypolipidemic/antiatherogenic drugs, nicotinic acid and pyridinol carbamate. Pirozadil is also shown to significantly diminish vascular cerebral resistance to a much greater degree than nicotinic acid and pyridinol carbamate[1]. | ||||||||||||
| Name | Pirozadil | ||||||||||||
| CAS | 54110-25-7 | ||||||||||||
| Formula | C27H29NO10 | ||||||||||||
| Molar Mass | 527.52 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Roca J, et al. Effect of pirozadil on cerebral blood flow in anesthetized dogs. Methods Find Exp Clin Pharmacol. 1981 Nov-Dec;3(6):397-401. |